BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 30042065)

  • 41. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
    Innocenti F; Ou FS; Qu X; Zemla TJ; Niedzwiecki D; Tam R; Mahajan S; Goldberg RM; Bertagnolli MM; Blanke CD; Sanoff H; Atkins J; Polite B; Venook AP; Lenz HJ; Kabbarah O
    J Clin Oncol; 2019 May; 37(14):1217-1227. PubMed ID: 30865548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
    Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
    J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
    Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M
    BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
    Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
    J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations.
    Kawai T; Nyuya A; Mori Y; Tanaka T; Tanioka H; Yasui K; Toshima T; Taniguchi F; Shigeyasu K; Umeda Y; Fujiwara T; Okawaki M; Yamaguchi Y; Goel A; Nagasaka T
    Clin Epigenetics; 2021 May; 13(1):117. PubMed ID: 34034807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study.
    Wangefjord S; Sundström M; Zendehrokh N; Lindquist KE; Nodin B; Jirström K; Eberhard J
    Biol Sex Differ; 2013 Sep; 4(1):17. PubMed ID: 24020794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
    Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
    Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
    Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
    Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis.
    Chang SC; Lin PC; Lin JK; Lin CH; Yang SH; Liang WY; Chen WS; Jiang JK
    Ann Surg Oncol; 2016 Mar; 23(3):849-55. PubMed ID: 26471487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
    Peeters M; Oliner KS; Parker A; Siena S; Van Cutsem E; Huang J; Humblet Y; Van Laethem JL; André T; Wiezorek J; Reese D; Patterson SD
    Clin Cancer Res; 2013 Apr; 19(7):1902-12. PubMed ID: 23325582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer.
    Kim B; Park SJ; Cheon JH; Kim TI; Kim WH; Hong SP
    World J Gastroenterol; 2014 Apr; 20(15):4370-6. PubMed ID: 24764675
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers.
    Sato K; Kawazu M; Yamamoto Y; Ueno T; Kojima S; Nagae G; Abe H; Soda M; Oga T; Kohsaka S; Sai E; Yamashita Y; Iinuma H; Fukayama M; Aburatani H; Watanabe T; Mano H
    Clin Cancer Res; 2019 Jan; 25(1):378-389. PubMed ID: 30279230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
    Kosumi K; Hamada T; Zhang S; Liu L; da Silva A; Koh H; Twombly TS; Mima K; Morikawa T; Song M; Nowak JA; Nishihara R; Saltz LB; Niedzwiecki D; Ou FS; Zemla T; Mayer RJ; Baba H; Ng K; Giannakis M; Zhang X; Wu K; Giovannucci EL; Chan AT; Fuchs CS; Meyerhardt JA; Ogino S
    Eur J Cancer; 2019 Apr; 111():82-93. PubMed ID: 30826660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
    J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of Positively and Negatively Selected Driver Gene Mutations Associated With Colorectal Cancer With Microsatellite Instability.
    Jonchere V; Marisa L; Greene M; Virouleau A; Buhard O; Bertrand R; Svrcek M; Cervera P; Goloudina A; Guillerm E; Coulet F; Landman S; Ratovomanana T; Job S; Ayadi M; Elarouci N; Armenoult L; Merabtene F; Dumont S; Parc Y; Lefèvre JH; André T; Fléjou JF; Guilloux A; Collura A; de Reyniès A; Duval A
    Cell Mol Gastroenterol Hepatol; 2018; 6(3):277-300. PubMed ID: 30116770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.